icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Articles /

Sobi Publishes Q4 2024 Report: A Solid Ending to a Strong Year

Julian WestWednesday, Feb 5, 2025 2:32 am ET
3min read


Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024, marking a solid conclusion to a successful year. The company's total revenue increased by 9% at constant exchange rates (CER) to SEK 7,436 M (6,844 M), driven by strong performance in its haematology portfolio and strategic initiatives.

Haematology Revenue Growth

Sobi's haematology revenue increased by 22% at CER to SEK 4,487 M (3,640 M), primarily due to:

* Strong sales of Doptelet®, which grew by 114% to SEK 1,147 M (727 M).
* Launch sales of Altuvoct®, contributing SEK 302 M (2 M) to the portfolio.
* Higher than expected sales of Vonjo®, reaching SEK 416 M (322 M).
* Growth in sales of Aspaveli®/Empaveli®, which increased by 69% to SEK 269 M (186 M).

These products contributed significantly to the overall growth of the haematology portfolio in Q4 2024.

Immunology Revenue Decline

Immunology revenue decreased by 12% at CER to SEK 2,564 M (2,905 M), mainly due to:

* Low Synagis® sales, which fell by 92% to SEK 68 M (897 M).
* Although Beyfortus® royalty and Kineret® sales partially offset this decline, the overall immunology revenue decreased.

The strategic portfolio, which includes Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant®, Vonjo, and Zynlonta®, as well as royalties on Sanofi's sales of Altuviiio® and Beyfortus, grew by 50% at CER to SEK 4,099 M (2,722 M). This contributed significantly to the overall revenue growth in haematology.

Financial Performance

The adjusted EBITA margin was 34% (38%), excluding items affecting comparability (IAC). EBITA was SEK 2,572 M (2,502 M), corresponding to a margin of 35% (37%). EBIT was SEK 1,662 M (1,610 M). Earnings per share (EPS) before dilution was SEK 4.07 (3.02), and adjusted EPS before dilution was SEK 4.03 (3.21). Cash flow from operating activities was SEK 1,797 M (1,073 M).

Outlook

Sobi anticipates revenue to grow by a high single-digit percentage at CER in 2025, with the adjusted EBITA margin expected to be in the mid-30s percentage of revenue. The company will not propose a dividend for the 2024 financial year.


SOBR Total Revenue


In conclusion, Sobi's Q4 2024 report demonstrates a strong finish to a successful year, with haematology revenue growth driven by key products and strategic initiatives. The company's outlook for 2025 remains positive, with expectations for continued revenue growth and a mid-30s adjusted EBITA margin.
Comments

Add a public comment...
Post
User avatar and name identifying the post author
FirmMarket4692
02/05
Doptelet's growth is 🚀 insane, holding for long
0
Reply
User avatar and name identifying the post author
FaatmanSlim
02/05
Haematology dominance makes $SOBI a solid play.
0
Reply
User avatar and name identifying the post author
JSOAN321
02/05
Altuvoct launch was a masterstroke, watch this space.
0
Reply
User avatar and name identifying the post author
Excellent-Win-4625
02/05
Sobi's strategic moves are on point, bullish vibes.
0
Reply
User avatar and name identifying the post author
mrkitanakahn
02/05
@Excellent-Win-4625 What do you think about their immunology segment?
0
Reply
User avatar and name identifying the post author
freekittykitty
02/05
@Excellent-Win-4625 Totally agree, Sobi's on a roll.
0
Reply
User avatar and name identifying the post author
Throwaway7131923
02/05
Doptelet's growth is wild, 114%? That's some next-level rocketship stuff. 🚀
0
Reply
User avatar and name identifying the post author
CarterUdy02
02/05
Sobi's strategic moves are paying off big time. That 50% growth in strategic portfolio is lit.
0
Reply
User avatar and name identifying the post author
DumbStocker
02/05
@CarterUdy02 Sobi's moves r pretty clutch.
0
Reply
User avatar and name identifying the post author
KookyPossibleTheme
02/05
@CarterUdy02 Lol, 50% growth ain't no joke, but Doptelet's 114% pop is the real MVP.
0
Reply
User avatar and name identifying the post author
Tryingtodoit23
02/05
Doptelet's 114% growth is wild, anyone else thinking about loading up on $SOBI?
0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App